查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1587471

液態切片市場規模、佔有率、趨勢分析報告：按循環生物標記、按應用、按地區、細分市場預測，2025-2030 年

Breast Cancer Liquid Biopsy Market Size, Share & Trends Analysis Report By Circulating Biomarkers (Circulating Tumor Cells, Circulating Cell-free DNA, Extracellular Vesicles), By Application, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

液態切片市場成長和趨勢：

預計2030年全球液態切片市場規模將達19億美元，2025年至2030年複合年成長率預計為8.5%。

這種成長的推動因素是人們對無創技術的日益偏好、早期診斷和治療意識的提高以及乳癌盛行率的上升。例如，根據世界衛生組織的數據，2020年全球有68.5萬名女性死於乳癌，230萬名女性被診斷出罹患乳癌。液態切片被認為是乳癌早期檢測的突破性技術，這正在推動乳癌的採用並刺激成長。

隨著乳癌盛行率的不斷增加，迫切需要提供適當的診斷工具來早期發現和早期治療癌症。為了滿足日益成長的需求，診斷領域的研究和開發變得更加活躍。例如，2022年6月，BioFluidica研究結果顯示，HER2陽性乳癌患者在接受量身定做的HER2定向治療時成功率有所提高。由於相關領域的進步，液態切片的臨床意義越來越為人所知。需要進一步的介入臨床試驗和創建適當結合循環生物標記的演算法，以使這些技術廣泛應用。

由於循環生物標記持續研究的技術突破，已經開發出用於識別非骨髓惡性腫瘤的侵入性較小的技術。與傳統的腫瘤切片檢查相比，液態切片被認為是即時患者監測的有前途的選擇。例如，2022 年 4 月，Epic Sc​​iences, Inc. 在其 CLIA 實驗室產品組合中添加了 DefineMBC，這是一種基於液態切片技術的血液檢測，用於診斷轉移性乳癌。

此外，該市場的主要企業都致力於擴大和推出可用於廣泛應用的產品。資料，2022年6月，NeoGenomics子公司Inivata Limited推出了RaDaR檢測方法，用於分析人類表皮生長因子受體2（HER2）陰性、患有微量殘存疾病（MRD）和復發的高風險患者。

液態切片市場報告亮點

  • 循環性腫瘤細胞(CTC) 領域預計在預測期內將以 9.4% 的最快複合年成長率成長。目前正在進行調查以確定 CTC 在早期乳癌中的效用。
  • 由於液態切片在癌症早期檢測中的使用不斷增加，預計早期檢測/篩檢領域在預測期內將以 9.7% 的複合年成長率顯著成長。
  • 按應用來看，由早期治療需求驅動的治療選擇細分市場以 2024 年 51.5% 的最大收益佔有率引領市場。
  • 在液態切片市場中，北美地區佔據最大收益佔有率，2024年為44.64%。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章液態切片市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 液態切片市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章液態切片市場：循環生物標記的估計和趨勢分析

  • 細分儀表板
  • 液態切片市場：循環生物標記的波動分析
  • 循環生物標記對液態切片市場的展望
  • 2018-2030年市場規模、預測及趨勢分析
    • 循環性腫瘤細胞(CTC)
    • 循環細胞 - 遊離 DNA (Cfdna)
    • 細胞外囊泡 (Evs)
    • 其他循環生物標記

第5章液態切片市場：應用估算與趨勢分析

  • 細分儀表板
  • 液態切片市場：應用變化分析
  • 按應用分類的液態切片市場前景
  • 2018-2030年市場規模、預測及趨勢分析
    • 早期發現/篩檢
    • 診斷
    • 治療選擇
    • 監控

第6章液態切片市場：區域估計和趨勢分析

  • 區域儀表板
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭格局

  • 市場參與企業分類
  • 主要市場參與企業的最新趨勢和影響分析
  • 主要企業市場佔有率，2024年
  • 主要企業簡介
    • The Menarini Group
    • NeoGenomics Laboratories
    • F. Hoffmann-La Roche Ltd.,
    • Myriad Genetics, Inc.
    • Thermo Fisher Scientific, Inc.
    • QIAGEN
    • Biocept, Inc.
    • Sysmex Corporation
    • Fluxion Biosciences, Inc.
    • Epic Sciences, Inc.
Product Code: GVR-4-68039-991-9

Breast Cancer Liquid Biopsy Market Growth & Trends:

The global breast cancer liquid biopsy market size is expected to reach USD 1.90 billion in 2030 and is projected to grow at a CAGR of 8.5% from 2025 to 2030. The growth is attributed to the rising preference for non-invasive methods, rising awareness of early diagnosis and treatment, and rising prevalence of breast cancer. For instance, according to WHO, in 2020, globally, 685,000 women lost their lives to breast cancer, and 2.3 million women were affected by it. Liquid biopsies have been suggested as a revolutionary technique for the early identification of breast cancer, which boosts its adoption and spurs growth.

With the increasing prevalence of breast cancer, there is a high demand to provide proper diagnostics tools for detecting cancer at an early stage and early treatment. There has been increasing R&D in the field of diagnostics to cater to the rising demand. For instance, in June 2022, according to study findings from BioFluidica, patients with HER2-positive breast cancer had success rates while receiving tailored HER2-directed therapy.The clinical significance of liquid biopsy is becoming more well-known as a result of ongoing developments in related fields. Additional interventional clinical trials and the creation of an algorithm to properly combine circulating biomarkers are required to make these technologies widely accessible.

A less intrusive technique for identifying non-hematological malignancies has been developed as a result of technological breakthroughs in continuing research on circulating biomarkers. Compared to traditional tumor biopsy, liquid biopsy is thought to be a promising option for patient monitoring in real time. For instance, in April 2022, Epic Sciences, Inc., launched DefineMBC, a blood test based on liquid biopsy technology for the diagnosis of metastatic breast cancer to its CLIA laboratory portfolio.

Furthermore, key players operating in the market are focusing on expanding and launching products that can be used for a wide range of applications. For instance, in June 2022, NeoGenomics's subsidiary Inivata Limited announced new data for RaDaR assay for the analysis of human epidermal growth factor receptor 2 (HER2)-negative, high-risk patients with minimal residual disease (MRD) and recurrence.

Breast Cancer Liquid Biopsy Market Report Highlights:

  • The circulating tumor cells (CTCs) segment is anticipated to grow at the fastest CAGR of 9.4% over the forecast period. There has been ongoing research to specify the utility of CTCs in early-stage breast cancer
  • The early detection/screening segment is expected to grow at a significant CAGR of 9.7% during the forecast period, due to the increasing application of the use of liquid biopsy in the early detection of cancer.
  • Based on application, the treatment selection segments led the market with the largest revenue share of 51.5% in 2024, attributed to the need to provide early treatment
  • North America dominated the breast cancer liquid biopsy market with the largest revenue share of 44.64% in 2024.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Circulating Biomarkers
    • 1.2.2. Application
    • 1.2.3. Regional Scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Circulating Biomarkers outlook
    • 2.2.2. Application outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Breast Cancer Liquid Biopsy Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing Prevalence Of Breast Cancer
      • 3.2.1.2. Increasing Adoption Of Liquid Biopsies In Cancer Diagnosis
      • 3.2.1.3. Need To Provide Early Diagnosis And Treatment
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High Cost Associated With Breast Cancer Liquid Biopsy Tests
      • 3.2.2.2. Regulatory & Reimbursement Hurdles
  • 3.3. Breast Cancer Liquid Biopsy Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Breast Cancer Liquid Biopsy Market: Circulating Biomarkers Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Breast Cancer Liquid Biopsy Market: Circulating Biomarkers Movement Analysis
  • 4.3. Breast Cancer Liquid Biopsy Market by Circulating Biomarkers Outlook (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Circulating Tumor Cells (Ctcs)
      • 4.4.1.1. Circulating Tumor Cells (Ctcs) Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 4.4.2. Circulating Cell - Free Dna (Cfdna)
      • 4.4.2.1. Circulating Cell - Free Dna (Cfdna) Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 4.4.3. Extracellular Vesicles (Evs)
      • 4.4.3.1. Extracellular Vesicles (Evs) Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 4.4.4. Other Circulating Biomarkers
      • 4.4.4.1. Other Circulating Biomarkers Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 5. Breast Cancer Liquid Biopsy Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Breast Cancer Liquid Biopsy Market: Application Movement Analysis
  • 5.3. Breast Cancer Liquid Biopsy Market by Application Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Early Detection/Screening
      • 5.4.1.1. Early Detection/Screening Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.4.2. Diagnosis
      • 5.4.2.1. Diagnosis Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.4.3. Treatment Selection
      • 5.4.3.1. Treatment Selection Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.4.4. Monitoring
      • 5.4.4.1. Monitoring Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6. Breast Cancer Liquid Biopsy Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Dashboard
  • 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3. North America
    • 6.3.1. U.S.
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework/ reimbursement structure
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.2. Canada
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework/ reimbursement structure
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.3. Mexico
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Regulatory framework/ reimbursement structure
      • 6.3.3.3. Competitive scenario
      • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. France
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework/ reimbursement structure
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework/ reimbursement structure
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Norway
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework/ reimbursement structure
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Regulatory framework/ reimbursement structure
      • 6.4.7.3. Competitive scenario
      • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Regulatory framework/ reimbursement structure
      • 6.4.8.3. Competitive scenario
      • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. China
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. India
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.5. South Korea
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.6. Thailand
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Argentina
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Market Participant Categorization
  • 7.2. Recent Developments & Impact Analysis by Key Market Participants
  • 7.3. Key company market share, 2024
  • 7.4. Key Company Profiles
    • 7.4.1. The Menarini Group
      • 7.4.1.1. Company Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. NeoGenomics Laboratories
      • 7.4.2.1. Company Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. F. Hoffmann - La Roche Ltd.,
      • 7.4.3.1. Company Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. Myriad Genetics, Inc.
      • 7.4.4.1. Company Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. Thermo Fisher Scientific, Inc.
      • 7.4.5.1. Company Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. QIAGEN
      • 7.4.6.1. Company Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. Biocept, Inc.
      • 7.4.7.1. Company Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. Sysmex Corporation
      • 7.4.8.1. Company Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Strategic Initiatives
    • 7.4.9. Fluxion Biosciences, Inc.
      • 7.4.9.1. Company Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Strategic Initiatives
    • 7.4.10. Epic Sciences, Inc.
      • 7.4.10.1. Company Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Strategic Initiatives

List of Tables

  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviations
  • Table 3. Global Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 4. Global Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 5. Global Breast Cancer Liquid Biopsy Market, by region, 2018 - 2030 (USD Million)
  • Table 6. North America Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 7. North America Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 8. U.S. Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 9. U.S. Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 10. Mexico Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 11. Mexico Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 12. Canada Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 13. Canada Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 14. Europe Breast Cancer Liquid Biopsy Market, by country, 2018 - 2030 (USD Million)
  • Table 15. Europe Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 16. Europe Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 17. UK Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 18. UK Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 19. Germany Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 20. Germany Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 21. France Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 22. France Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 23. Italy Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 24. Italy Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 25. Spain Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 26. Spain Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 27. Denmark Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 28. Denmark Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 29. Norway Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 30. Norway Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 31. Sweden Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 32. Sweden Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 33. Asia Pacific Breast Cancer Liquid Biopsy Market, by country, 2018 - 2030 (USD Million)
  • Table 34. Asia Pacific Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 35. Asia Pacific Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 36. Japan Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 37. Japan Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 38. China Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 39. China Breast Cancer Liquid Biopsy Market, by application 2018 - 2030 (USD Million)
  • Table 40. India Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 41. India Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 42. Australia Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 43. Australia Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 44. South Korea Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 45. South Korea Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 46. Thailand Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 47. Thailand Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 48. Latin America Breast Cancer Liquid Biopsy Market, by country, 2018 - 2030 (USD Million)
  • Table 49. Latin America Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 50. Latin America Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 51. Brazil Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 52. Brazil Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 53. Argentina Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 54. Argentina Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 55. Middle East & Africa Breast Cancer Liquid Biopsy Market, by country, 2018 - 2030 (USD Million)
  • Table 56. Middle East & Africa Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 57. Middle East & Africa Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 58. South Africa Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 59. South Africa Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 60. Saudi Arabia Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 61. Saudi Arabia Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 62. UAE Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 63. UAE Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 64. Kuwait Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 65. Kuwait Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information procurement
  • Fig. 2 Primary research pattern
  • Fig. 3 Market research approaches
  • Fig. 4 Value chain-based sizing & forecasting
  • Fig. 5 Market formulation & validation
  • Fig. 6 Breast Cancer Liquid Biopsy Market segmentation
  • Fig. 7 Market driver analysis (current & future impact)
  • Fig. 8 Market restraint analysis (current & future impact)
  • Fig. 9 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 10 Porter's five forces analysis
  • Fig. 11 Breast Cancer Liquid Biopsy Market, Circulating Biomarkers outlook key takeaways (USD Million)
  • Fig. 12 Breast Cancer Liquid Biopsy Market: Circulating Biomarkers movement analysis (USD Million), 2024 & 2030
  • Fig. 13 Circulating Tumor Cells (Ctcs) market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 14 Circulating Cell - Free Dna (Cfdna) market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 15 Extracellular Vesicles (Evs) market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 16 Other Circulating Biomarkers market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 17 Early Detection/Screening market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 Diagnosis market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Treatment Selection market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Monitoring market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Breast Cancer Liquid Biopsy Market: regional key takeaways (USD Million)
  • Fig. 22 Breast Cancer Liquid Biopsy Market: regional outlook, 2023 & 2030, USD Million
  • Fig. 23 North America Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 U.S. Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Canada Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Mexico Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Europe Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 UK Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Germany Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 France Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Spain Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Italy Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Norway Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Denmark Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Sweden Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Asia Pacific Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 China Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Japan Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 India Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 South Korea Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Australia Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Thailand Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Latin America Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Brazil Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Argentina Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Middle East and Africa Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 South Africa Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Saudi Arabia Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 UAE Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Kuwait Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 List of key emerging company's/liquid biopsy disruptors/innovators